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INTRODUCTION
Modern anti-diabetic agents targeting nuclear receptors are designed to modulate blood glucose levels and gene expression on a molecular level. Transcriptional regulation by agonists of peroxisome proliferator-activated receptor (PPAR)γ, PPARα and LXR comprise genes involved in gluconeogenesis, fatty acid metabolism and ketogenesis Venkateswaran et al., 2000) . PPARγ is a critical transcription factor involved in energy balance and activated by well-established anti-diabetic drugs, the thiazolidinediones (Lehmann et al., 1995) . Nuclear receptor agonist or fatty acid dependent activation of PPARα promotes peroxisomal proliferation, hepatic fatty acid oxidation and the generation of ketone bodies thereby providing substrates for energy metabolism in peripheral tissues (Issemann and Green, 1990) . LXRα, the predominant LXR paralogue in liver regulates intracellular cholesterol and bile acid metabolism as well as expression of sterol regulatory binding protein (SREBP)-1c, the major lipogenic transcription factor (Schultz et al., 2000; Repa et al., 2000) . Activation of LXR is associated with down-regulation of key genes involved in hepatic gluconeogenesis (Stulnig et al., 2002a; Cao et al., 2003; Laffitte et al., 2003) . Moreover, nuclear receptors can modulate each other's gene expression as shown for PPARγ and LXRα (Ide et al., 2003; Seo et al., 2004) pointing to a close relation of their transcriptional regulations and metabolic function. Agonists of PPARγ, PPARα and LXR all decrease blood glucose concentrations in type 2 diabetes patients and/or comparable animal models (Lehmann et al., 1995; Guerre-Millo et al., 2000; Laffitte et al., 2003) by regulating gene expression. In order to address the question whether normalization of blood glucose levels by these nuclear receptor agonists is accompanied by normalized gene expression, we analyzed genome-wide hepatic gene expression profiles of diabetic db/db mice treated with nuclear receptor agonists and their untreated non-diabetic littermates and compared them with given p-value threshold to the number of positives actually found (Irizarry, 2003; Storey and Tibshirani, 2003) . Using this statistical approach comparisons of gene expression with absolute fold changes of at least 1.5-fold (increase or decrease) were selected at p<0.01 as a default and p<0.001 where indicated. Abbreviation, annotation and analyses of genes meeting the selection criteria were done by combining available information from Affymetrix, Applied Biosystems (PANTHER), Jax, Genelynx, Kegg, Ensembl, Swiss-Prot and PubMed in a Filemaker Pro database.
MATERIAL AND METHODS
Animals
Hierarchical clustering analysis.
Genes altered by treatment with all nuclear receptor agonists by at least 1.5-fold (in either direction) and at p < 0.01 between mean gene expression and untreated db/db animals were selected for a cluster analysis. The genes were clustered using a distance measure defined as 1 minus the correlation between gene pair 
RESULTS
Metabolic data. This study was performed to elucidate to which extent blood glucoselowering nuclear receptor agonists alter hepatic gene expression profiles of obese diabetic mice in convergence to non-diabetic animals. Gene expression profiles of db/db mice treated with agonists of PPARγ (Rosi), PPARα (Wy) and LXR (T09) and untreated db/+ mice were compared to untreated diabetic mice. Treatment with each of the compounds resulted in reductions in blood glucose concentrations near to those of non-diabetic mice (Table 1) .
Plasma insulin concentrations were significantly increased only in the T09-treated group indicating that stimulation of insulin secretion as shown for cultured pancreatic islets and β-cells (Efanov, 2004) could also occur in vivo. Body weight remained constant during the treatment except a borderline (p = 0.088) increase in the Rosi group. The Wy and particularly T09-treated animals showed significant hepatomegaly with increased liver to body weight ratio by 1.8 and 2.5-fold, respectively, due to the known development of hepatic steatosis by T09 as revealed by highly elevated hepatic triglyceride contents in T09-treated db/db mice (Table 1) .
Gene expression profiling. Gene expression profiles were evaluated using 12k oligonucleotide microarrays for 3 individual mice of each group and robust multiarray analysis. A p-value of < 0.01 was predefined together with a fold change of
as selection criteria for profile comparisons including detection of functional groups. 337 genes were altered in untreated diabetic vs. non-diabetic mice (Table 2 ). Drug treatment of db/db mice elicited significant changes in the expression of a comparable number of genes, namely 300, 620, and 735 genes for Rosi, Wy, and T09, respectively. Estimated false discovery rates (FDR) were between 6-11% for p < 0.01 but about 80% of genes were altered at a p < 0.001 with FDR of 1-3%, respectively, indicating excellent confidence of data.
Moreover, standardized logarithmic expression estimates from microarrays highly correlated This article has not been copyedited and formatted. The final version may differ from this version. 1A) . In total, only a set of 19 genes (6%) were normalized by all blood glucose lowering drugs (listed in Supplementary Figure 1A ) indicating that these genes could be particularly important in mediating the glucose lowering effects. These genes included some with clear implication in glucose metabolism and diabetes such as those involved in gluconeogenesis (e.g., glucose-6-phosphatase, fructose-1,6-bisphosphatase) and the glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1, whereas the functional implication of others for glucose lowering have to be assessed in detail. However, 56 (17%), 85 (25%) and 59 (18%) genes altered in db/db vs db/+ mice were regulated by Rosi, Wy and T09, respectively, in the direction opposite to diabetes -1 (Fig. 1B) . The 30 genes Gluconeogenesis. Hepatic gluconeogenesis and glucose output is significantly enhanced in type 2 diabetes patients and comparable mouse models and contributes to high blood glucose levels. Treatment with each of the blood glucose lowering nuclear receptor agonists resulted in normalization of gluconeogenetic key enzyme gene expression as shown for phosphoenol pyruvate carboxykinase 1 (PEPCK; gene Pck1; 1.2 fold; p < 0.05), fructose-1,6-bisphosphatase (Fbp1) and the catalytic and transport units of glucose-6-phosphatase (G-6-Pase; G6pc and G6pt1) (Fig. 2) . Interestingly, the PPARα agonist treatment led to an increased expression of fructose-2,6-bisphosphatase (Fbp2) which could imply an additional regulation of Fbp1 through competitive inhibition by fructose-2,6-bisphosphate. Expression of aldolase B (Aldo2) that catalyzes cleavage of fructose-1,6-bisphosphate and functions as a feed forward activator of pyruvate kinase was normalized by both Wy (-1.8 fold; p < 0.002) and Rosi (-1.4 fold; p = 0.042). Glucokinase (Gck) whose expression was increased by 1.4
fold in diabetes -1 , was normalized in the Rosi group (1.4 fold; p = 0.003) and T09 group (1.8 fold; p < 0.001). Additional transfer of glucose-6-phosphate through the pentose phosphate shunt in the LXR-treated group is indicated by elevated expression of Gck, X-linked glucose-6-phosphate dehydrogenase (G6pdx), glucose-6-phosphate dehydrogenase 2 (G6pd2), ribose 5-phosphate isomerase A (Ripa) and transketolase (Tkt; Supplementary Figure 3) . In general these data indicate that treatment of db/db mice with different blood glucose lowering nuclear receptor agonist resulted in normalized expression of key genes involved in glucose homeostasis even though some genes were regulated in an agonist-specific manner.
This article has not been copyedited and formatted. The final version may differ from this version. (Ntambi et al., 2002) . Hepatic gene expression of lipogenic enzymes, e.g., stearoyl-Coenzyme A desaturase 1 (Scd1), was generally increased in db/db vs db/+ animals (Fig. 3A) . Treatment of db/db mice with any blood glucose lowering compound led to a further strong increase of Scd1 gene expression (Fig. 3A) . Scd1 expression is regulated by sterol regulatory element-binding protein-(SREBP)-1c-dependent and independent mechanisms (Miyazaki et al., 2004) . Since induction of Scd1 by drugs correlated with elevated SREBP-1c expression levels only in the T09 group (Fig. 3A) , Scd1 upregulation by PPAR agonists appears to occur predominantly by SREPB1c-independent mechanisms. Parallel to Scd1 expression, fatty acid synthase (Fasn) and glycerol-3-phosphate acyltransferase (Gpam) was strongly induced by treatment with any agonist whereas expression of hepatic lipase was decreased (Fig. 3A) . Thereby, the nuclear receptor agonists aggravated diabetes-associated alterations in lipogenesis in parallel with their glucose lowering effect (Way et al., 2001) . Such regulation opposite to diabetes -1 could on the one hand indicate enhancement of adaptive processes that were already induced by diabetes itself but also worsening of detrimental diabetes-associated alterations. Recent data suggest that upregulation of lipogenesis provides an effective means to inhibit diabetes development by shifting the lipogenic burden from adipose tissue to the liver (Nadler and Attie, 2001) . Altogether alterations in hepatic lipid homeostasis provoked hepatic triglyceride accumulation particularly in the T09-treated and -to a lesser extent -in Rosi-treated animals.
Moreover, the LXR agonist increased blood plasma triglyceride concentrations, whereas Rosi and Wy lowered plasma triglyceride concentrations (Table 1; Mitochondrial and peroxisomal β-oxidation. β-oxidation of free fatty acids provides energy and substrates for ketogenesis. Expression of genes implicated in mitochondrial fatty acid import including the carnitine acyltransferase Crat and the translocase Slc25a20 (Ramsay et al., 2001; Sekoguchi et al., 2003) . Expression of both genes was significantly increased in diabetic vs. non-diabetic mice and further elevated by treatment with blood glucose-lowering nuclear receptor agonists indicating augmented mitochondrial fatty acid import (Fig. 3B) .
Expression of the long chain-specific carnitine acyltransferases (Cpt1a, Cpt2) was increased by diabetes and further elevated in response to Wy treatment. Expression of enzymes involved in mitochondrial fatty acyl oxidation such as dodecenoyl-Coenzyme A delta isomerase (Dci) and t acetyl-CoA dehydrogenases (Acads, Acadm, Acadl) was somewhat increased in diabetic animals and further elevated by nuclear receptor agonists ( Fig. 3C and Supplementary Figure 3) . Peroxisomes oxidize fatty acids by different pathways with preference for long chain and very long chain fatty acids (Van Veldhoven and Mannaerts, 1999) . Expression of enzymes of the classical pathway, namely acyl-Coenzyme A oxidase 1 (Acox1), enoyl-Coenzyme A hydratase/3-hydroxyacyl Coenzyme A dehydrogenase (Ehhadh) and acetyl-Coenzyme A acyltransferase 1 (Acaa1) was more pronounced in db/db vs. db/+ animals (Lan et al., 2003) and further increased by nuclear receptor agonist treatment, particularly Wy (Fig. 3C ) in parallel with peroxisomal biogenesis factor 11a (Pex11a; Fig.   3C ). Notably, hepatic triglyceride accumulation particularly in T09-treated animals revealed that increased β-oxidation did not sufficiantly counteract elevated lipogenesis to prevent hepatic steatosis. Increased ketogenesis in diabetes was indicated by elevated expression of key genes 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (Hmgcs2) and 3-hydroxy-3-methylglutaryl-Coenzyme A lyase (Hmgcl; Fig. 3D ketogenesis. In conclusion, treatment with different blood glucose-lowering nuclear receptor agonists resulted in increased expression of most genes contributing to mitochondrial and peroxisomal fatty acid oxidation and ketogenesis thereby aggravating the diabetes-associated shift to fatty acid metabolism.
Glucocorticoid activation. Type 2 diabetes has been shown to be associated with alterations in local activation of inactive glucocorticoid precursors (cortisone, 11-dehydro corticosterone) to active glucocorticoids (corticosterone, cortisol) by 11β-hydroxysteroid dehydrogenase type 1 (Hsd11b1). Hsd11b1 is particularly expressed in human and rodent liver and adipose tissue (Bujalska et al., 2002) and increased expression has been linked to development of diabetes and the metabolic syndrome (Masuzaki et al., 2001; Aoki et al., 2001 ). Treatment with agonists of the PPAR and LXR family has been shown recently to affect expression of Hsd11b1 in adipose tissue and liver (Stulnig et al., 2002b; Cao et al., 2003) . Treatment of either nuclear receptor agonists diminished Hsd11b1 expression even below the level of non-diabetic mice (Fig. 4) . Since oxo-reductase activity of Hsd11b1 depends on NADPH, mutations in hexose-6-phosphate dehydrogenase (H6pd) synergize with weak Hsd11b1 mutations in glucocorticoid activation (Draper et al., 2003) . However, H6pd gene expression was not changed in this study (Fig. 4) . Notably, Hsd11b1 was one of the only 19 transcripts that were normalized by all blood glucose lowering nuclear receptor agonists ( Supplementary Fig. 1A ). These data emphasize the importance of 11β-hydroxysteroid dehydrogenase 1 for the development of insulin resistance and suggest the use of specific inhibitors of this enzyme in diabetes treatment.
Growth hormone signaling. Growth hormone (GH) antagonizes insulin signaling and elicits insulin resistance resulting in increased hepatic glucose production. In contrast to unchanged expression in diabetic vs. non-diabetic mice, treatment with blood nuclear receptor agonists downregulated growth hormone receptor gene (Ghr) expression (Fig. 5) , whose abundance is related to GH tissue sensitivity (Dominici and Turyn, 2002; Iida et al., 2004) , as well as expression of insulin-like growth factor-1 (Igf-1), a prototype GH-responsive gene in the liver. These data indicate interference with GH action by nuclear receptor agonist treatment. Since inhibition of GH action improves insulin sensitivity (Yakar et al., 2004) , this could be an additional mechanism how PPAR and LXR agonists ameliorate glucose homeostasis in diabetes.
Endoplasmic reticulum stress. Endoplasmic reticulum stress is a major contributor for the development of obesity and insulin resistance as shown very recently (Özcan et al., 2004) .
Obesity triggers an unfolded protein response (UPR) in liver that is controlled by X-boxbinding protein-1 (XBP-1) (Yoshida et al., 2001) . Notably, XBP-1 +/-mice are prone to insulin resistance due to impaired insulin signal transduction during endoplasmic reticulum stress (Özcan et al., 2004) . Glucose-regulated/binding immunoglobulin protein Grp78
(Hspa5), an endoplasmic reticulum chaperone, and the protein kinase inhibitor p58 ipk (Dnajc3) are upregulated during UPR and the latter has been shown to be a XBP-1 target gene as is thioredoxin domain containing protein-7 (Txndc7) (Lee et al., 2003) . XBP-1 expression was significantly lowered by all blood glucose-lowering nuclear receptor agonists ( 18 expression (Efanov, 2004) have to be addressed first. Notably, the model for type 2 diabetes used here cannot discriminate between alterations induced by diabetes or obesity alone, respectively. Hence changes provoked by obesity but not by metabolic derangements cannot be overcome by the action of the compounds that did not induce weight loss. However, alterations induced by obesity and metabolic derangements are usually combined also in type 2 diabetes patients.
In conclusion, this study revealed that apart from pointing to novel modes of action, currently available blood glucose-lowering nuclear receptor agonists by far do not normalize diabetes-associated molecular alterations. Despite our advances during recent years, there is still a need for developing novel drugs for effective treatment of type 2 diabetes at the molecular level. Gene expression was evaluated by QPCR (default; n=5) or by microarrays (indicated by black dot; n=3) and is given in percent of that in untreated db/db mice. G6pc, glucose-6-phosphatase, catalytic subunit; G6pt, glucose-6-phosphatase, transport subunit; PEPCK (Pck1), phosphoenolpyruvate carboxykinase 1, cytosolic; Fbp1, fructose bisphosphatase 1; Aldo2, aldolase 2, B isoform; ut, untreated. Significant differences compared to untreated db/db are indicated as follows: *, p < 0.05; †, p < 0.01; ‡, p < 0.001. (indicated by black dot; n=3) and is given in percent of that in untreated db/db mice.
Hsd11b1, hydroxysteroid 11-beta dehydrogenase 1; H6pd, hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase); ut, untreated. Significant differences compared to untreated db/db are indicated as follows: ‡, p < 0.001. 
